Literature DB >> 15944297

B lymphocyte activation by human papillomavirus-like particles directly induces Ig class switch recombination via TLR4-MyD88.

Rongcun Yang1, Francisco Martinez Murillo, Michael J Delannoy, R Lee Blosser, William H Yutzy, Satoshi Uematsu, Kiyoshi Takeda, Shizuo Akira, Raphael P Viscidi, Richard B S Roden.   

Abstract

Vaccination with human papillomavirus type 16 (HPV16) L1 virus-like particles (VLP) induces both high titer neutralizing IgG and protective immunity. Because protection from experimental infection by papillomavirus is mediated by neutralizing IgG, we sought the mechanisms that trigger humoral immunity to HPV16 L1 VLP. We find that HPV16 L1 VLP bind to murine B lymphocytes thereby inducing activation-induced cytidine deaminase expression and Ig class switch recombination to cause the generation of IgG. HPV16 L1 VLP also activate production of proinflammatory factors IFN-alpha, IL-6, MIP-1alpha, RANTES, and KC, up-regulate the expression of costimulatory molecules by naive B cells, and increase the B1 B cell subpopulation. These B cell responses to HPV16 L1 VLP are dependent upon MyD88. Although MyD88(-/-) B cells produce only mu transcript after exposure to HPV16 L1 VLP, MyD88(+/+) B cells express alpha, gamma, and mu Ig H chain and activation-induced cytidine deaminase transcripts. Notably, TLR4 mutant C3H/HeJ mice exhibited significantly reduced HPV16 VLP-specific IgG1, IgG2a, IgG2b, and IgG3 titers after vaccination as compared with the control C3H/HeOuJ mice. HPV16 L1 VLP directly activated class switch recombination and costimulatory molecule expression by B cells of C3H/HeOuJ mice but not C3H/HeJ mice. Thus HPV16 L1 VLP directly activate B cells to induce CD4(+) T cell independent humoral immune responses via TLR4- and MyD88-dependent signaling.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15944297     DOI: 10.4049/jimmunol.174.12.7912

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  32 in total

Review 1.  Antibody polyspecificity and neutralization of HIV-1: a hypothesis.

Authors:  Barton F Haynes; M Anthony Moody; Laurent Verkoczy; Garnett Kelsoe; S Munir Alam
Journal:  Hum Antibodies       Date:  2005

2.  CD4+ T cells are not required for the induction of dengue virus-specific CD8+ T cell or antibody responses but contribute to protection after vaccination.

Authors:  Lauren E Yauch; Tyler R Prestwood; Monica M May; Malika M Morar; Raphaël M Zellweger; Bjoern Peters; Alessandro Sette; Sujan Shresta
Journal:  J Immunol       Date:  2010-09-24       Impact factor: 5.422

3.  Association between toll-like receptor expression and human papillomavirus type 16 persistence.

Authors:  Ibrahim I Daud; Mark E Scott; Yifei Ma; Stephen Shiboski; Sepideh Farhat; Anna-Barbara Moscicki
Journal:  Int J Cancer       Date:  2011-02-15       Impact factor: 7.396

Review 4.  Integration of B cell responses through Toll-like receptors and antigen receptors.

Authors:  David J Rawlings; Marc A Schwartz; Shaun W Jackson; Almut Meyer-Bahlburg
Journal:  Nat Rev Immunol       Date:  2012-03-16       Impact factor: 53.106

5.  Influence of Brucella abortus lipopolysaccharide as an adjuvant on the immunogenicity of HPV-16 L1VLP vaccine in mice.

Authors:  Zahra Kianmehr; Hoorieh Soleimanjahi; Susan Kaboudanian Ardestani; Fatemeh Fotouhi; Asghar Abdoli
Journal:  Med Microbiol Immunol       Date:  2014-09-04       Impact factor: 3.402

6.  Insights into the Role of Innate Immunity in Cervicovaginal Papillomavirus Infection from Studies Using Gene-Deficient Mice.

Authors:  Carolina Scagnolari; Fabiana Cannella; Alessandra Pierangeli; Rebecca Mellinger Pilgrim; Guido Antonelli; Dayana Rowley; Margaret Wong; Simon Best; Deyin Xing; Richard B S Roden; Raphael Viscidi
Journal:  J Virol       Date:  2020-06-01       Impact factor: 5.103

7.  A direct comparison of human papillomavirus type 16 L1 particles reveals a lower immunogenicity of capsomeres than viruslike particles with respect to the induced antibody response.

Authors:  Nadja Thönes; Anna Herreiner; Lysann Schädlich; Konrad Piuko; Martin Müller
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

8.  Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials.

Authors:  John T Schiller; Douglas R Lowy
Journal:  J Infect Dis       Date:  2009-07-15       Impact factor: 5.226

9.  Sublingual immunization with nonreplicating antigens induces antibody-forming cells and cytotoxic T cells in the female genital tract mucosa and protects against genital papillomavirus infection.

Authors:  Nicolas Cuburu; Mi-Na Kweon; Catherine Hervouet; Hye-Ran Cha; Yuk-Ying S Pang; Jan Holmgren; Konrad Stadler; John T Schiller; Fabienne Anjuère; Cecil Czerkinsky
Journal:  J Immunol       Date:  2009-12-15       Impact factor: 5.422

Review 10.  Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions.

Authors:  Shreya Kanodia; Diane M Da Silva; W Martin Kast
Journal:  Int J Cancer       Date:  2008-01-15       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.